What causes clinical trial site activation delays?

Site activation is usually delayed by the steps that must be finished before a trial starts: contract and budget agreement, ethics and regulatory approvals, essential records, product supply, and staff who are qualified, trained and delegated (ICH E6(R3) C.2.5).

Each step waits on the one before, so one late item holds up the rest.

The gates a site has to pass

  • Agreements: the sponsor should document agreements with the investigator or institution before activities start (ICH E6(R3) 3.6.1), and contract and budget negotiation often runs longest.
  • Ethics review: the investigator needs dated, documented IRB or IEC approval or favorable opinion before starting (ICH E6(R3) 2.4.2).
  • Regulatory submissions where required, before the trial begins (ICH E6(R3) 3.8.1).
  • Product: investigational product should be supplied only after the required approvals (ICH E6(R3) 3.15.3(a)).
  • People: the sponsor confirms the investigator and site staff have adequate qualifications, resources and facilities (ICH E6(R3) 3.11.4.5.2(a)), and delegated staff need trial-specific training (ICH E6(R3) 2.3.2).
  • Systems: users must be trained and given access to each trial system (ICH E6(R3) 4.3.2).

Where the time usually goes

Delays tend to come from waiting rather than work: a contract sitting in a legal queue, a document returned for a missing signature, a coordinator who left after site selection, or system accounts requested only after the initiation visit. Staffing gaps are the hardest to see from outside, because a site can look ready on paper while the people named on its delegation record have changed.

What sponsors and sites can check early

  • Ask for the current delegation record and training records at selection, not at activation.
  • Run approvals, contracts and training in parallel where the rules allow, and keep one shared tracker.
  • Request system access for every delegated user as soon as their names are known.
  • Check that the people trained at the initiation visit are still the people who will run the study.

Questions people also ask

What is the difference between site selection and site activation?

Selection is choosing a site that has the qualifications, resources and facilities (ICH E6(R3) 3.7.1); activation is the sponsor's go-ahead once approvals, agreements, records and training are in place.

Can a site start before the contract is signed?

Generally no. ICH E6(R3) expects agreements to be documented before activities start (ICH E6(R3) 3.6.1), and sponsors usually require a signed agreement before shipping product.

Which essential records hold up activation most often?

Missing signatures and dates, outdated CVs, training records that do not match the delegation record, and IRB documents for the wrong consent version.

How can a sponsor check staff readiness before activation?

By looking at evidence of each delegated person's training and judgment on the decisions the protocol depends on, not only at a list of names and certificates.

Primary sources

  • ICH E6(R3) Guideline for Good Clinical Practice, final version adopted 6 January 2025 (ICH): https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf
  • E6(R3) Good Clinical Practice, final guidance (U.S. Food and Drug Administration): https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r3-good-clinical-practice-gcp
  • 21 CFR 312.53: Selecting investigators and monitors (eCFR): https://www.ecfr.gov/current/title-21/section-312.53

Last reviewed

2026-11-14